Sihuan Pharmaceutical Announces Second Anti-Virus Partnership With AMMS
Sihuan Pharma announced a second anti-viral collaboration with the Institute of Microbiology and Epidemiology of the Academy of Military Medical Sciences (AMMS). The newest project involves BR-01, an anti-adenovirus drug. The collaboration follows less than a week behind an agreement between Sihuan and AMMS for joint development of an AMMS-developed Ebola treatment. Sihuan expects BR-01 will prove effective as both a preventative and treatment for a broad spectrum of virus-caused illnesses. Financial terms of the collaboration were not made public.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.